The blood-brain barrier (BBB) is a complex and dynamic structure that protects the brain from harmful substances, but also limits the delivery of therapeutic agents for various brain diseases. Our laboratory is interested in developing novel strategies to overcome the BBB and deliver drugs to the brain efficiently and selectively. One of our main approaches is to use receptor-mediated transcytosis (RMT), a process that allows the transport of molecules across the BBB via specific receptors on the endothelial cells. We design and synthesize drug conjugates that can bind to these receptors and trigger their internalization and transcytosis. We also investigate the molecular mechanisms and regulation of RMT, as well as the pharmacokinetics and pharmacodynamics of our drug conjugates. We use various in vitro and in vivo models to test the efficacy and safety of our drug delivery systems for different brain diseases, such as Alzheimer’s disease, Parkinson’s disease, stroke, brain tumors, and infections. Our goal is to provide new insights and solutions for brain drug delivery and improve the treatment outcomes for patients with neurological disorders.

This research aims to explore the potential of intranasal drug delivery for brain targeting, bypassing the blood-brain barrier. We will investigate the transport capacity and rate of different drugs via the olfactory and trigeminal routes, using various formulations, devices, and models.

We invented device called 'Jerryseat' that keeps the mouse in a head-down position to enhance the efficiency of nose-to-brain delivery. 

Our laboratory is interested in developing novel strategies to inhibit RCD(Regulated cell death), especially apoptosis and caspases, for the treatment of various diseases. We have studied the role and regulation of RCD in different disease models, such as rheumatoid arthritis, age-related macular degeneration (AMD), ischemia, hepatitis, and cancer. We have designed and synthesized inhibitors of apoptosis and caspases, such as siRNA, peptides. We have also explored different delivery systems to enhance the stability, specificity, and bioavailability of our inhibitors. We use various in vitro and in vivo methods to test the efficacy and safety of our inhibitors for different diseases. Our goal is to provide new insights and solutions for modulating RCD and improve the treatment outcomes for patients with RCD-related disorders.